

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 8-K

ELITE PHARMACEUTICALS INC /DE/  
Form 8-K  
August 08, 2003

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15 (D)  
OF THE SECURITIES EXCHANGE ACT OF 1934

August 8, 2003

-----  
(Date of Report)

ELITE PHARMACEUTICALS, INC.

-----  
(Exact name of registrant as specified in its charter)

Delaware	333-45241	22-3542636
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

165 Ludlow Avenue Northvale, New Jersey 07647

-----  
(Address of principal executive offices)

201 750-2646

-----  
(Registrant's telephone number, including area code)

Item 5. Other Events and Regulation FD Disclosure

On August 8, 2003, Registrant issued a press release disclosing that its Board of Directors has authorized its officers to negotiate a merger agreement with Nostrum Pharmaceuticals Inc., a privately-held developer of drug delivery products ("Nostrum") to provide for the acquisition of Nostrum in exchange for shares of Registrant's Common Stock and options to acquire additional shares of Registrant's Common Stock. See Item 7(c). No assurance can be given that any agreement will be executed or, if executed, that any transaction will result therefor.

Item 7. Financial Statements and Exhibits

- a) Not applicable.
- b) Not applicable.
- c) Exhibits.

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 8-K

Exhibit No. -----	Document Description -----
99.1	Copy of Press Release dated August 8, 2003

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DATED: AUGUST 8, 2003

ELITE PHARMACEUTICALS, INC.

By: /s/ Mark Gittelman

-----  
Name: Mark Gittelman  
Title: Chief Financial Officer